Rome-Modern has no plans to share its COVID-19 vaccine, as executives have concluded that increasing the company’s own production is the best way to increase global supply.
In an interview with the Associated Press, Nobar Afyan reiterated Modern’s pledge a year ago that it would not enforce patent infringement on anyone else who develops the corona virus vaccine during infectious diseases.
“We didn’t have to do that,” Afyan said. “We thought it was the right thing to do.” He added: “We want it to help the world.”
The UN health agency has pressured Modern to share its vaccine formula. Afyan said the company analyzed whether it would be better to share Messenger RNA technology and vowed to increase production in 2022 and provide billions of extra food.
“Within the next six to nine months, the most reliable and effective way to make high-quality vaccines is if we make them,” Afyan said. Asked about appeals from the World Health Organization and others, he said such requests assumed “we can’t get enough capacity, but in reality we know we can.”
Modern has “taken 1 billion doses in less than a year from zero production,” said Afrin, citing a Massachusetts-based company sprint to develop the vaccine and make it in large quantities. And we think we can go from 1 to 3 billion in 2022.
“We understand that we are doing everything we can to help fight this epidemic,” Afin said, referring to the company’s growing productivity and its commitment to patent infringement.
He noted that 2.5 2.5 billion and 10 years were spent developing the platform that makes the modern COVID-19 vaccine.
“Other people joined the hunt when the Cove 19 came out, and we’re glad to see that it has greatly increased its capacity, which Modern could not do on its own,” said Afyan.
When asked how many others he thinks could be successful if he started using modern patents, he declined to speculate. But “it’s hard for me to imagine that they will be able to achieve any reasonable scale in such a short time frame that we can confidently work for 2022.”
Asked about the recent criticism that Modern is not providing its vaccines primarily to rich countries while low-income countries are clamoring for the product, Affian said the company has provided “significant” production to poor countries. Of course, mostly through his work with the US government. At the beginning of the epidemic, a food contract was signed with the company.
The executive said Modern is working with a number of governments to “help low-income countries secure their supplies for a clear purpose”.
“The European Union and the US government have far more supplies than they can use,” said Afyan, who is also a co-founder of Modern.
Separately, Moderna promised in May to the UN-backed vaccine program Quakes that a total of 500 million doses would be arranged to reach poor countries. He said that about 40 million doses would start arriving in the last three months of this year, with the rest to be delivered next year.